Janus Henderson Investors US’s Acadia Pharmaceuticals ACAD Stock Holding History

Janus Henderson Investors US’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$118M	Buy	3,418,861 +26,690	+0.8%	+$942K	0.1%	263
2016 Q4	$97.8M	Buy	3,392,171 +195,089	+6%	+$5.16M	0.08%	302
2016 Q3	$102M	Sell	3,197,082 -4,533	-0.1%	-$154K	0.09%	299
2016 Q2	$104M	Buy	3,201,615 +503,549	+19%	+$16.9M	0.09%	282
2016 Q1	$75.4M	Buy	2,698,066 +1,071,819	+66%	+$23.4M	0.07%	338
2015 Q4	$58M	Buy	1,626,247 +6,710	+0.4%	+$236K	0.05%	383
2015 Q3	$53.6M	Sell	1,619,537 -1,400,975	-46%	-$58.3M	0.05%	400
2015 Q2	$126M	Buy	3,020,512 +206,363	+7%	+$7.99M	0.1%	262
2015 Q1	$91.7M	Buy	2,814,149 +160,767	+6%	+$5.53M	0.08%	327
2014 Q4	$84.2M	Buy	2,653,382 +40,039	+2%	+$1.14M	0.07%	341
2014 Q3	$64.7M	Buy	2,613,343 +1,300,618	+99%	+$30.4M	0.06%	365
2014 Q2	$29.7M	Buy	1,312,725 +82,916	+7%	+$1.73M	0.03%	505
2014 Q1	$29.9M	Buy	1,229,809 +296,816	+32%	+$7.51M	0.03%	496
2013 Q4	$23.3M	Buy	+932,993	New	+$22M	0.02%	515

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Janus Henderson Investors US's ACAD Position: Q1 2017 in Review

Janus Henderson Investors US increased its Acadia Pharmaceuticals (ACAD) stake by 0.79% in Q1 2017, buying an estimated $942K and bringing the position to 3,418,861 shares worth $118M. The position accounts for 0.1% of the portfolio, ranked #263.

Janus Henderson Investors US first reported a position in ACAD in Q4 2013 and has held it in 14 quarters since. The position peaked at $126M in Q2 2015. 219 funds tracked by Wall St. Rank hold ACAD as of Q1 2017.

Janus Henderson Investors US held 3,418,861 shares of Acadia Pharmaceuticals worth $118M as of Q1 2017.
Janus Henderson Investors US bought 26,690 Acadia Pharmaceuticals shares in Q1 2017, an estimated $942K.
Acadia Pharmaceuticals made up 0.1% of Janus Henderson Investors US's portfolio in Q1 2017, its #263 holding.
Janus Henderson Investors US first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
Janus Henderson Investors US's Acadia Pharmaceuticals position peaked at $126M in Q2 2015.
219 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.